Quantum Genesis AI confirms CEO assignment of ibuprofen synthesis patent

Quantum Genesis AI Corp.

CEO Naveen Kulkarni assigned all rights in US Patent App. US20250146029A1 for enzymatic ibuprofen synthesis to the company.
Assignment effective as of Nov. 2, 2023, formalizing a prior 2023 Asset Purchase Agreement.
Company will amend FY2025 10-K and FY2026 Q1 & Q2 10-Qs to update IP disclosures.
No new consideration; agreement confirms existing ownership.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Quantum Genesis AI Corp. entered into Intellectual Property Assignment Agreement with Naveen Kulkarni (effective 2026-04-09).

Action: entry
Counterparty: Naveen Kulkarni
Effective: 2026-04-09

Exact text from the filing

On April 9, 2026, Quantum Genesis AI Corp. (the “Company”) entered into a confirmatory Intellectual Property Assignment Agreement (the “Assignment Agreement”) with Naveen Kulkarni, the Company’s Chief Executive Officer (the “Assignor”).

View on SEC.gov

85 material agreements filed in the last 30 days. Browse all material agreements →

Quantum Genesis AI Corp. filing history →

Source: SEC EDGAR

accession 0001477932-26-002252

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.